The verdict
Our read at a glance.
Whether the clinical evidence in catabolic illness supports its use for physique in healthy people.
- The signal
- The clinical work is real and specific to sick populations: nandrolone has been studied for anaemia and muscle wasting in chronic kidney disease and dialysis, in HIV-associated wasting, and in other catabolic states, where added lean mass in a wasting patient is itself the therapeutic goal. Contemporary registered trials still examine it in defined clinical settings. None of that literature was designed to answer whether a healthy trained person benefits, and the endpoints that matter clinically in a dialysis patient are not the endpoints a lifter cares about.
- The unknown
- What prolonged use does to the axis in healthy men. Nandrolone's suppression is notably deep and slow to reverse, and there is no controlled long-term recovery data in this population.
- Our read
- A drug whose medical résumé is doing a lot of work it did not earn. Being useful in a dialysis patient with wasting says nothing about a healthy person adding mass, and the specific liability here - deep, long progestogenic suppression - is the one most often hand-waved away.
The mechanism
How it works.
Nandrolone is testosterone with the carbon-19 methyl group removed, which is why it is called 19-nortestosterone. That single change alters what happens to it in tissue. It is a strong androgen receptor agonist in muscle, but it is a poor substrate for aromatase, so it produces relatively little oestradiol, and 5-alpha-reductase converts it to dihydronandrolone, which is a weaker androgen rather than a stronger one - the reverse of what happens to testosterone. That is the basis of its reputation for being anabolic with less androgenic load. The complication is that the same structure gives it appreciable activity at the progesterone receptor, and progestogenic signalling suppresses the gonadal axis and can drive sexual dysfunction through a route that has nothing to do with oestrogen.
Safety & regulatory boundary
The consequential part.
A Schedule III controlled substance in the United States. Its 19-nor structure gives it meaningful progestogenic activity, which is the mechanistic basis for the sexual dysfunction users report and which is not fixed by managing oestrogen alone. It suppresses endogenous testosterone strongly and for a long time after the last injection, and its metabolites are detectable in urine for many months, which is why it accounts for a large share of anti-doping violations. Prohibited in sport at all times.
What's next
What we're watching.
Any modern controlled data on recovery of the gonadal axis after prolonged use, and continued clinical work in dialysis and wasting.
Context
Why this is discussed.
It is one of the two or three most-used injectable steroids, credited with joint comfort and steady mass gain, and it has a genuine medical history that makes it feel safer than the alternatives.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · NA · ENROLLING_BY_INVITATION · 2026-03-12
ClinicalTrials.gov · PHASE2 · RECRUITING · 2023-08-10
ClinicalTrials.gov · PHASE4 · NOT_YET_RECRUITING · 2025-01
ClinicalTrials.gov · PHASE4 · NOT_YET_RECRUITING · 2025-01
ClinicalTrials.gov · PHASE1/PHASE2 · COMPLETED · 2014-02-01
ClinicalTrials.gov · PHASE2/PHASE3 · COMPLETED · 2000-07
ClinicalTrials.gov · NA · UNKNOWN · 2020-12-01
ClinicalTrials.gov · PHASE1 · COMPLETED · registry record
Indexed literature (PubMed)12
Hemmersbach P et al. · Handb Exp Pharmacol · 2010
Niromand E et al. · Steroids · 2021
Geusens P · Clin Rheumatol · 1995
Kohler RM et al. · Br J Sports Med · 2002
Busardò FP et al. · Curr Neuropharmacol · 2015
Dantas PS et al. · Steroids · 2021
Zelleroth S et al. · Behav Brain Res · 2022
Alves FL et al. · Naunyn Schmiedebergs Arch Pharmacol · 2024
Ali YH et al. · Burns · 2022
Shirpoor A et al. · Steroids · 2024
Polet M et al. · Drug Test Anal · 2024
Salimi Z et al. · Neurosci Res · 2020
Keep reading